Clinical Trials Logo

Clinical Trial Summary

This is a randomized, double blind, placebo-controlled, phase II study. The study will be performed as a multicenter, multinational study.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04487860
Study type Interventional
Source Sun Pharmaceutical Industries Limited
Contact
Status Completed
Phase Phase 2
Start date January 6, 2021
Completion date February 22, 2023

See also
  Status Clinical Trial Phase
Completed NCT04052425 - Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1) Phase 3
Completed NCT04057573 - Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) Phase 3
Completed NCT04942860 - The Evaluation of Vitiligous Lesions Repigmentation After Topical Administration of Methotrexate in Patients With Active Vitiligo Phase 3
Recruiting NCT06113328 - A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007) Phase 2
Recruiting NCT01377077 - Punchgrafting Techniques for Vitiligo Phase 4
Completed NCT04927975 - Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo Phase 2
Active, not recruiting NCT04811326 - Latanoprost Plus NB-UVB Versus Each Alone in Non-segmental Vitiligo: Clinical and Laboratory Evaluation Phase 4
Terminated NCT03022019 - ReNovaCell in Non-segmental Vitiligo N/A
Completed NCT03247400 - The Evaluation of Vitiligous Lesions Repigmentation After the Administration of Atorvastatin Calcium Salt and Simvastatin-acid Sodium Salt in Patients With Active Vitiligo Phase 1/Phase 2
Not yet recruiting NCT05990309 - ASSESSMENT OF TRISTETRAPROLIN EXPRESSION IN LESIONAL SKIN OF PATIENTS WITH NON SEGMENTAL VITILIGO N/A